

We would like to acknowledge that we are gathered today on the traditional territories of the Musqueam, Squamish and Tsleil-Waututh peoples.

Source: [www.ihomaps.net/na/canada/bc/vancouver/firstnations/firstnations.html](http://www.ihomaps.net/na/canada/bc/vancouver/firstnations/firstnations.html)




# When should I worry about my patient's numbness and tingling in their limbs ?



## VCH Family & Community Practice rounds

Amokrane Chebini MD FRCPC CSCN (EMG)  
Clinical Assistant Professor  
Division of Neurology  
UBC

March 25th, 2026



# Disclosures

- None



# Objectives

- Subacute (and acute) causes of peripheral neuropathy
- Brief approach to paraproteinemia and peripheral neuropathy
- When to expand the workup beyond the basic metabolic screen
- Red flags for alternative causes of numbness and tingling



Providing an overview on specific diseases but also a general approach

Please stop me anytime during the presentation if you have questions

I have [integrated](#) a few cases as well

# "polyneuropathy," vs "peripheral neuropathy," vs "neuropathy"

**Polyneuropathy** refers to generalized process that affects multiple different nerves, *predominantly* affecting the distal nerves

**Peripheral neuropathy** usually used **synonymously** with polyneuropathy, but *technically* any disorder of the peripheral nervous system, which may include radiculopathies and mononeuropathies.

**Neuropathy**, even less specific term and can include disorders of the central and peripheral nervous system.



# Clinical case

67-year-old man with a 3-month history of progressively worsening sensation of buzzing and tingling sensation in the feet but progressed over 1 week to his hands. He is also unsteady on his feet

PHMx is unremarkable but he consumes a “couple of beers” a day.

He takes vitamin supplementation but no other regular medications

He has no family history of neuromuscular disorders.



# Clinical case

Neurological examination : reduced sensation to all sensory modalities (pinprick, temperature, vibration and proprioception) to mid-shins in legs and wrists in the arms. Strength was normal, and deep tendon reflexes were absent at the ankles.



# Clinical case

What are the red flags in this case ?

- 3-month subacute progression
- Early involvement of the hands
- Early unsteadiness gait

Which vitamin supplementation is he taking ?



# Clinical case

What are the red flags in this case ?

- 3-month subacute progression
- Early involvement of the hands
- Early unsteadiness gait
- Which vitamin supplementation is he taking ?
- Turns out he takes four tablets of a "daily nerve health supplement". Each tablet included **50 mg vitamin B6**, for a **total daily dose of 200 mg**.



# Atypical/red flags features



## Typical length-dependent peripheral neuropathy

### Features include

- Sensory involvement more prominent than motor
- Symmetric signs and symptoms
- More severe in most distal extremities (eg, toes and feet)
- Symptom onset and progression over months to years

### Laboratory evaluations to determine etiology

- ▶ Fasting blood glucose
- ▶ Serum B<sub>12</sub> with methylmalonic acid
- ▶ Serum protein electrophoresis with immunofixation
- ▶ Hemoglobin A<sub>1c</sub> with fasting glucose

### Common etiologies include

- Diabetes
- Nutrition imbalance (eg, B<sub>12</sub>, copper, thiamine)
- Alcohol use disorder
- Medication toxicity (see Table 2)
- Monoclonal gammopathies
- Hereditary

## Atypical peripheral neuropathy

### Features include

- Severe motor weakness or autonomic symptoms
- Non-length-dependent pattern of sensory loss or weakness
- Asymmetric pattern of sensory and/or motor impairment
- Systemic signs and symptoms (eg, weight loss, fever, rash)
- Symptom onset and progression over days to weeks

### Refer to neuromuscular specialist

- ▶ Laboratory testing for immune, inflammatory, infectious, or neoplastic etiologies
- ▶ Autonomic testing (eg, quantitative sudomotor axon reflex test, heart rate response to deep breathing, Valsalva maneuver, tilt table) for those with prominent autonomic symptoms
- ▶ Lumbar puncture, nerve imaging, and nerve biopsy may also be considered

## Box 26–1. Acute Polyneuropathies

Guillain–Barré syndrome

Porphyria

Diphtheria

Drugs (e.g., dapson, nitrofurantoin, vincristine)

Toxins (e.g., arsenic, thallium, triorthocresylphosphate)

Tick paralysis

Vasculitis

# Nitrofurantoin


- Risk factor: Renal failure
- Neuropathy
  - Acute (*how many doses/days of therapy ??*)
  - Can be Motor predominant
  - Sensory: Paresthesias
  - Distribution: Distal > proximal; Symmetric
  - Recovery
    - Stop drug at 1st sign of neuropathy
    - **Often only partial**




## Neuropathy:

Peripheral neuropathy, which may become severe or irreversible, has occurred. Fatalities have been reported. Conditions such as renal impairment (creatinine clearance under 60 mL per minute or clinically significant elevated serum creatinine), anemia, diabetes mellitus, electrolyte imbalance, vitamin B deficiency, and debilitating disease may enhance the occurrence of peripheral neuropathy. Patients receiving long-term therapy should be monitored periodically for changes in renal function.




# Vasculitic neuropathy



# Vasculitic neuropathy



# Mononeuritis multiplex



# Mononeuritis multiplex



- Acute focal, painful neuropathy --> subacutely over days to weeks to involve other regions of the body
- **Asymmetrical** (legs often affected first)
- Pain is a sensitive feature and present in > 90 percent of patients
  - **Sharp achy pain** followed by more **typical neuropathic features** such as burning, tingling, and a warm/cold sensation

# Mononeuritis multiplex



- **Fever, malaise, and weight loss** are present in most patients with **systemic vasculitis**.
- Less common and milder in patients with nonsystemic vasculitic neuropathy, with weight loss (30%) and fever (10-15%) still seen

# Mononeuritis multiplex

## Systemic vasculitis

• **Palpable purpura or skin ulcers** seen in small- or medium-vessel vasculitis (such as **granulomatosis with polyangiitis [GPA]**)




# Mononeuritis multiplex

## Systemic vasculitis




- Destructive upper airway lesions in GPA;
- Asthma, allergic rhinitis, and/or nasal polyps in eosinophilic granulomatosis with polyangiitis [EGPA; Churg-Strauss]
- Alveolar hemorrhage in all forms



# Diagnosis of vasculitic neuropathy

- Nerve biopsy is **required** for diagnosis (*nuanced in systemic vasculitis*)
- **Intramural inflammation** accompanied by pathologic evidence of **vascular wall damage**
- **Sensitivity is only about 50%.. 65%** when combined with muscle biopsy



# Nonsystemic vasculitic neuropathy



- Requires **URGENT** treatment
- **High-dose glucocorticoids plus glucocorticoid-sparing agent**
  - azathioprine vs methotrexate vs cyclophosphamide

**Back to our case...**



# Clinical case


What are the red flags in this case ?

- 3-month subacute progression
- Early involvement of the hands
- Early unsteadiness gait
  
- **Which vitamin supplementation is he taking ?**
  - Turns out he takes our tablets of a "daily nerve health supplement". Each tablet included 50 mg vitamin B6, for a **total daily dose of 200 mg.**



# Metabolic cases


## B6 (pyridoxine) toxicity



- Direct damage to the **dorsal root ganglia (DRG)** sensory neurons
- **Irreversible ganglionopathy** that may worsen for weeks following discontinuation of vitamin B6
  - sensory ataxia with unsteady gait and pseudoathetoid posturing
- Toxicity with excessive supplementation usually **more than 2 g/d**, but **long-standing (> 6 months) use of 50 mg/d** also describes in the literature
- *My general rule is no more than 50 mg/d if needed for as short as possible (cramps for example)*

# Metabolic cases

## B6 (pyridoxine) deficiency



- Deficiency due to poor oral intake is **uncommon**
- Occurs most commonly with **isoniazid** use for TB treatment (standard of care to provide supplementation during treatment)
- Sensory-predominant axonal length-dependent peripheral neuropathy
- Replacement therapy for vitamin B6 deficiency is 50 mg/d orally (**if CLEAR deficiency present**)

# Clinical case

- A 19-year-old female presenting with **difficulty walking** and **leg numbness** over **1 week**. She noted **foot drop** and **paresthesia** in her hands as well. **Urinary urgency** present. Neurological review of systems negative otherwise
- No systemic symptoms.
- Studies political sciences in University.
- Denies THC, ETOH, smoking cigarettes



# Clinical case

## EXAM

- Upper limb examination was normal.
- Lower limb strength **severe weakness of ankle dorsiflexion and eversion and mild weakness of plantarflexion and inversion.**
- **Lower limb reflexes were absent and the right plantar was upgoing.**
- **He had reduced pinprick perception to the ankles with reduced vibration sense and proprioception at the toes.**



# Clinical case



- What other questions may we ask here ?


# Clinical case

- On **specific questioning**, reports using nitrous oxide for the past 5 years and was using up to **60 bottles per day at presentation**
- Vitamin B12 level normal at 300 ; **next steps ?**



# Metabolic cases

B12





# Metabolic cases

## B12

### Risk factors


- Strict vegan diet.
- **Poor gastrointestinal absorption** : atrophic gastritis, gastric bypass, prolonged proton pump inhibitor use, pernicious anemia, IBD such as Crohn disease, surgical resection of the ileum
- **Nitrous oxide causes functional Vitamin B12 deficiency**



# Metabolic cases

B12

- "*subacute combined degeneration of the spinal cord*"
- Classic triad of **sensory ataxia, posterior column dysfunction, and spastic paraparesis**
- Mixed upper and lower motor neuron signs (**absent ankle reflexes with upgoing toe**).



# Metabolic cases

## B12

**MMA and homocysteine normal** – No deficiency of vitamin B12 or folate.


**MMA and homocysteine elevated** – Deficiency of vitamin B12 (**some normal homocysteine and elevated MMA**)

**MMA normal, homocysteine elevated** – No deficiency of vitamin B12. Could be deficiency of folate but not diagnostic.



# Metabolic cases

## B12



# Metabolic/toxic



## Nitrous Oxide

**Nitrous oxide** oxidizes cobalt ions in vitamin B12 (cobalamin), resulting in inactive methylcobalamin (a physiologically active form of B12)

**EMG/NCS** - May lead an acute or subacute onset distal and **motor predominant axonal neuropathy**

### Treatment :

- **STOP nitrous oxide**
- High-dose intramuscular B12 (eg, 1mg every 2 days for 11 doses), followed by long-term replacement
- Neurological recovery can often be slow and may be incomplete

# Red flags for cervical MYELOPATHY

- Early onset of sensory symptoms in the hands
- Early issues with dexterity
- B/B dysfunction
- Pyramidal distribution of weakness (preferential weakness of upper limb extensors and lower limb flexors)
- Brisk reflexes (look for Hoffman's sign, upgoing toes)
- Gait instability early on



# Toxic causes

## Alcohol



- About **46% in individuals** with chronic AUD
- Usually, length dependent sensorimotor polyneuropathy
- Direct alcohol toxicity and vitamin deficiencies
- **\*\* common cause of SMALL fiber neuropathy \*\***
- Advice all patients with polyneuropathy to reduce and stop ETOH

# Case #3

- 42 y.o male with **3-month history** of swelling in feet and difficulty lifting his right leg going upstairs.
- Over a **matter of a few weeks**, symptoms evolved to diffuse limb weakness and sensory loss spreading from toes to knees.
- Also reports **erectile dysfunction**, intermittent bouts of **severe abdominal pain**



# Case #3

- Exam showed LE swelling, flushing and UE hypertrichosis, palpable axillary and inguinal adenopathy, hepatosplenomegaly
- Diffuse weakness distal > proximal, LE > UE
- Hyporeflexic in the upper limbs and areflexic in the lower limbs.
- Sensation reduced to vibration, joint position, and pinprick below the knees
- Positive Romberg sign



# Case #3

Next steps ?



# Case #3



Broad workup important given the several red flags

# Case #3

Platelets : 1349

SPEP/UPEP normal

Serum free light chains :

**Kappa light chains:** 23.9 mg/L

*Normal range: 3.3-19.4 mg/L*

**Lambda light chains:** 84.7 mg/L

*Normal range: 5.7-26.3 mg/L*

**Kappa to lambda ratio:** 0.28

*Normal range: 0.26-1.65*



# Case #3



**NCS** : axonal greater than demyelinating length-dependent peripheral neuropathy without evidence of conduction block or temporal dispersion.

# Case #3



Any initial thoughts ?  
Any other investigations ?

# Case #3



**LP** – protein 2.35 g/L (**VERY high**)

**CT abdo/pelvis** : moderate splenomegaly with three nonspecific bone lesions felt to be benign.

# Case #3

Trial of IVIG for a **presumed diagnosis of CIDP** – no clinical improvement

**PET CT scan** : expansile lytic lesion in the right ilium and right midhumerus and prominent fludeoxyglucose (FDG)-avid right axillary lymph nodes.

**VEGF level very high** (700 pg/mL, normal <96.2 pg/mL)

**Bone marrow biopsy** - 20% lambda light chain restricted plasma cells




# Case #3



Final diagnosis ?

**POEMS** [polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes] syndrome)

# Monoclonal gammopathy and neuropathy



# Monoclonal gammopathy and neuropathy

- **10% of patients** with PN have a monoclonal gammopathy (after NCS/EMG) (but most are incidental)
- More common with **IgM** than with IgA or IgG monoclonal proteins.
- Monoclonal gammopathies occur in 3.2% of individuals older than 50 years and in 5% of those older than 70 years. **Their coexistence with PN may be coincidental.**
- Still referred to hematology for evaluation of plasma cell disorders
- **I tend to order SPEP/UPEP with all patients with neuropathy but is it truly mandatory ?**



# POEMS (POLYNEUROPATHY, ORGANOMEGALY, ENDOCRINOPATHY, MONOCLONAL PLASMA CELL DISORDER, AND SKIN CHANGES)



**Table 1** Diagnostic criteria for POEMS syndrome

## Criteria

Mandatory major criteria	1. Polyneuropathy 2. Monoclonal plasma cell proliferative disorder
Other major criteria (one required)	3. Castleman's disease 4. Sclerotic bone lesions 5. Raised vascular endothelial growth factor
Minor criteria	6. Organomegaly (spleen/liver/lymph nodes) 7. Extravascular volume overload 8. Endocrinopathy (adrenal, thyroid*, pituitary, gonadal, parathyroid, pancreatic*) 9. Skin changes 10. Papilloedema 11. Thrombocytosis/polycythaemia
Other useful features	Clubbing, weight loss, hyperhidrosis, pulmonary hypertension/restrictive lung disease, thrombotic diathesis, diarrhoea, low serum, vitamin B <sub>12</sub>

\*Due to high prevalence of thyroid disease and diabetes mellitus, this diagnosis alone is not sufficient to meet the criteria for endocrinopathy. POEMS, polyneuropathy, organomegaly, endocrinopathy, the presence of a monoclonal plasma cell disorder and skin disease.

# POEMS - Neuropathy

**Clinical** : Starts distally lower limbs with weakness (**often severe**) and sensory loss --> rapid progression to a **polyradiculoneuropathy** with proximal and distal weakness and loss of reflexes


**Pain is common** (less common in CIDP)

**Nerve conduction studies** shows primarily demyelinating length-dependent sensorimotor peripheral neuropathy vs diffuse polyradiculoneuropathy

**Less autonomic involvement** but erectile dysfunction



# POEMS – Key findings



- DADS- distal acquired demyelinating symmetric neuropathy (DADS-M)
  - Usually presents with distal but slowly progressive sensory loss in feet that can result in gait ataxia and sometimes tremor
  - No weakness or minimal (toe extension)
  - Sometimes can look like CIDP – more prominent weakness



# DADS (distal acquired demyelinating symmetric neuropathy)



- 50%-75% will have anti-MAG antibodies **(DADS-M)**
- 33-64% of patients with DADS do NOT have a monoclonal protein **(DADS-I)**.
- **DADS-I** responds to CIDP immunotherapy such as **IVIG**
- **DADS-M** less responsive and if insidious course, then I follow them clinically

# References

- Continuum (Minneap Minn). 2020;26(5, Peripheral Nerve and Motor Neuron Disorders):1257-1279.
- Mauermann ML, Staff NP. Peripheral neuropathy: a review. JAMA. 2026;335(3):255-266.
- Preston DC, Shapiro BE. Electromyography and neuromuscular disorders: clinical-electrophysiologic correlations. 3rd ed. Philadelphia (PA): Elsevier/Saunders; 2013.
- Collins MP, Dyck PJB. Clinical manifestations and diagnosis of vasculitic neuropathies. In: Goddeau RP, Eichler AF, editors. UpToDate [Internet]. Waltham (MA): UpToDate; 2026 [cited 2026 Mar 21]. Available from: <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-vasculitic-neuropathies>
- Diffuse alveolar hemorrhage. Radiopaedia [Internet]. [cited 2026 Mar 21]. Available from: <https://radiopaedia.org/articles/diffuse-alveolar-hemorrhage-1>
- U.S. Food and Drug Administration. Drug label information [Internet]. Silver Spring (MD): FDA; 2021 [cited 2026 Mar 21]. Available from: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/020064Orig1s029lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020064Orig1s029lbl.pdf)
- Washington University in St. Louis. Toxic neuropathies [Internet]. St. Louis (MO): Washington University; [cited 2026 Mar 21]. Available from: <https://neuromuscular.wustl.edu/nother/toxic.htm#nitrofurantoin>
- Smyth D, Kramarz C, Carr AS, et al. Toxic neuropathies: a practical approach. Pract Neurol. 2023;23(2):120-130.
- Continuum (Minneap Minn). 2020;26(5, Peripheral Nerve and Motor Neuron Disorders):1280-1298.
- Means RT Jr, Fairfield KM. Clinical manifestations and diagnosis of vitamin B12 and folate deficiency. In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; [updated 2024 May 3; cited 2026 Mar 21]. Available from: <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-vitamin-b12-and-folate-deficiency>
- Treatment of vitamin B12 and folate deficiencies. In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; [updated 2022; cited 2026 Mar 21]. Available from: <https://www.uptodate.com/contents/treatment-of-vitamin-b12-and-folate-deficiencies>
- Continuum (Minneap Minn). 2020;26(5, Peripheral Nerve and Motor Neuron Disorders):1369-1383.
- Rajkumar SV, Kumar S. Monoclonal gammopathy of undetermined significance. N Engl J Med. 2025;393(13):1315-1326. doi:10.1056/NEJMra2412716
- Keddie S, Keddie S, Keddie S, et al. POEMS neuropathy: optimising diagnosis and management. Pract Neurol. 2018;18(4):278-290.



# Finish line



THE UNIVERSITY OF BRITISH COLUMBIA

